Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BRNS
Upturn stock ratingUpturn stock rating

Barinthus Biotherapeutics plc (BRNS)

Upturn stock ratingUpturn stock rating
$0.92
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: BRNS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4.5

1 Year Target Price $4.5

Analysts Price Target For last 52 week
$4.5Target price
Low$0.64
Current$0.92
high$1.58

Analysis of Past Performance

Type Stock
Historic Profit -65.7%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.52M USD
Price to earnings Ratio -
1Y Target Price 4.5
Price to earnings Ratio -
1Y Target Price 4.5
Volume (30-day avg) 3
Beta -0.77
52 Weeks Range 0.64 - 1.58
Updated Date 07/1/2025
52 Weeks Range 0.64 - 1.58
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.64

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -332.22%

Management Effectiveness

Return on Assets (TTM) -18.2%
Return on Equity (TTM) -45.42%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -49679329
Price to Sales(TTM) 2.51
Enterprise Value -49679329
Price to Sales(TTM) 2.51
Enterprise Value to Revenue 0.62
Enterprise Value to EBITDA -6.67
Shares Outstanding 40339400
Shares Floating 35027907
Shares Outstanding 40339400
Shares Floating 35027907
Percent Insiders 14.45
Percent Institutions 44.67

Analyst Ratings

Rating 1
Target Price 4.5
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Barinthus Biotherapeutics plc

stock logo

Company Overview

overview logo History and Background

Barinthus Biotherapeutics plc (BRNS), formerly known as Vaccitech plc, is a biopharmaceutical company founded in 2010, spun out from Oxford University. It focuses on developing novel immunotherapeutic products and vaccines for infectious diseases and cancer. Key milestones include securing funding rounds, advancing clinical trials, and strategic partnerships. The company rebranded to Barinthus Biotherapeutics in 2024 to reflect its broader therapeutic focus.

business area logo Core Business Areas

  • Infectious Diseases: Developing vaccines and immunotherapies against infectious diseases, including chronic hepatitis B and shingles.
  • Oncology: Developing novel cancer immunotherapies, primarily focusing on T-cell stimulation to target tumors.

leadership logo Leadership and Structure

Bill Enright serves as the Chief Executive Officer. The company operates with a typical structure of a biopharmaceutical company, including research and development, clinical operations, and commercialization teams.

Top Products and Market Share

overview logo Key Offerings

  • VTP-300 (Chronic Hepatitis B): An immunotherapeutic designed to induce immune responses against hepatitis B virus. Currently in Phase 2b clinical trials. Competitors include Gilead Sciences (GILD) and Vir Biotechnology (VIR). No specific market share data available yet.
  • VTP-850 (Prostate Cancer): A cancer vaccine designed to target prostate cancer. Currently in Phase 1/2 clinical trials. Competitors include companies developing other cancer vaccines and immunotherapies such as Moderna (MRNA) and BioNTech (BNTX). No specific market share data available yet.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The sector is driven by innovation and unmet medical needs.

Positioning

Barinthus Biotherapeutics is a clinical-stage company with a focus on developing novel immunotherapies. Its competitive advantage lies in its proprietary platform technology and expertise in T-cell stimulation.

Total Addressable Market (TAM)

The global hepatitis B therapeutics market is projected to reach USD 4.8 billion by 2030. The cancer vaccine market is expected to reach USD 14.8 billion by 2030. Barinthus Biotherapeutics is positioned to capture a segment of these markets with its pipeline candidates.

Upturn SWOT Analysis

Strengths

  • Proprietary platform technology
  • Strong scientific team
  • Promising clinical trial results
  • Strategic collaborations with leading institutions

Weaknesses

  • Limited financial resources compared to larger competitors
  • Clinical trial risks and uncertainties
  • Dependence on successful development of pipeline candidates
  • No products currently generating revenue

Opportunities

  • Potential for breakthrough therapies in areas of unmet need
  • Expansion into new therapeutic areas
  • Partnerships with larger pharmaceutical companies
  • Favorable regulatory environment for innovative therapies

Threats

  • Competition from established pharmaceutical companies
  • Failure of clinical trials
  • Regulatory hurdles
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • VIR
  • MRNA
  • BNTX

Competitive Landscape

Barinthus Biotherapeutics competes with larger, more established pharmaceutical companies. Its advantage lies in its novel approach and expertise in T-cell stimulation. Disadvantages include limited financial resources and the risks associated with clinical-stage development.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by the advancement of pipeline candidates through clinical trials.

Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of products. Analyst estimates vary widely depending on the success of the pipeline.

Recent Initiatives: Recent initiatives include the initiation of new clinical trials, strategic partnerships, and strengthening the intellectual property portfolio.

Summary

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of immunotherapies and vaccines. It's currently not strong with no products commercially available. The company's expertise in T-cell stimulation and strategic partnerships are working well to advance clinical trials. Barinthus needs to monitor clinical trial outcomes and competition from larger companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Barinthus Biotherapeutics plc

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-04-30
CEO, Director & Principal Financial Officer Mr. William J. Enright MBA
Sector Healthcare
Industry Biotechnology
Full time employees 105
Full time employees 105

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.